Peritoneal fibrosis and epigenetic modulation

Perit Dial Int. 2021 Mar;41(2):168-178. doi: 10.1177/0896860820938239. Epub 2020 Jul 14.

Abstract

Peritoneal dialysis (PD) is an effective treatment for patients with end-stage renal disease. However, peritoneal fibrosis (PF) is a common complication that ultimately leads to ultrafiltration failure and discontinuation of PD after long-term PD therapy. There is currently no effective therapy to prevent or delay this pathologic process. Recent studies have reported epigenetic modifications involved in PF, and accumulating evidence suggests that epigenetic therapies may have the potential to prevent and treat PF clinically. The major epigenetic modifications in PF include DNA methylation, histone modification, and noncoding RNAs. The mechanisms of epigenetic regulation in PF are complex, predominantly involving modification of signaling molecules, transcriptional factors, and genes. This review will describe the mechanisms of epigenetic modulation in PF and discuss the possibility of targeting them to prevent and treat this complication.

Keywords: DNA methylation; epigenetic mechanisms; histone modifications; noncoding RNAs; peritoneal fibrosis.

Publication types

  • Review

MeSH terms

  • Epigenesis, Genetic
  • Humans
  • Peritoneal Dialysis* / adverse effects
  • Peritoneal Fibrosis* / genetics
  • Peritoneal Fibrosis* / pathology
  • Peritoneum / pathology
  • Signal Transduction